Studies have confirmed that high levels of CXCL5 are associated with high metastatic potential and poor survival rates in prostate cancer, colorectal cancer, hepatocellular carcinoma, and oral squamous cancers [13]–[16], [19]. This evidence concerns the gene CXCL5 and Familial prostate cancer.